p53-话题@MedSci

#p53#

137篇内容 | 5270人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1372460, encodeId=b0b713e2460e8, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=蜘蛛丝增强p53抗癌能力，有望开发出广谱mRNA癌症疫苗, objectType=article, longId=300988, objectId=49e230098827, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e230098827, replyNumber=0, likeNumber=118, createdTime=2022-03-18, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e230098827, moduleTitle=蜘蛛丝增强p53抗癌能力，有望开发出广谱mRNA癌症疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e230098827)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372459, encodeId=ebe213e245971, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=AJH：p53 蛋白亚型的表达可预测多发性骨髓瘤患者的生存率, objectType=article, longId=300096, objectId=7a5a30009665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5a30009665, replyNumber=0, likeNumber=120, createdTime=2022-03-06, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5a30009665, moduleTitle=AJH：p53 蛋白亚型的表达可预测多发性骨髓瘤患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5a30009665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372458, encodeId=85c713e2458fa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, objectType=article, longId=295258, objectId=d4ed295258b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ed295258b0, replyNumber=0, likeNumber=127, createdTime=2022-02-09, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ed295258b0, moduleTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ed295258b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372457, encodeId=86fe13e2457a5, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Cancers：新生儿筛查TP53 R337H变异检测和监测儿童肾上腺皮质肿瘤的早期诊断, objectType=article, longId=294007, objectId=fe7c29400e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7c29400e5f, replyNumber=0, likeNumber=98, createdTime=2022-01-16, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7c29400e5f, moduleTitle=Cancers：新生儿筛查TP53 R337H变异检测和监测儿童肾上腺皮质肿瘤的早期诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7c29400e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372456, encodeId=97f213e2456c8, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=291939, objectId=aea92919392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aea92919392a, replyNumber=0, likeNumber=123, createdTime=2021-12-17, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aea92919392a, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aea92919392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372455, encodeId=e62c13e245510, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, objectType=article, longId=218715, objectId=800e218e15c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=800e218e15c8, replyNumber=0, likeNumber=125, createdTime=2021-10-18, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=800e218e15c8, moduleTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=800e218e15c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372454, encodeId=02fa13e245460, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值, objectType=article, longId=218079, objectId=d7002180e97d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7002180e97d, replyNumber=0, likeNumber=129, createdTime=2021-10-05, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7002180e97d, moduleTitle=J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7002180e97d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372453, encodeId=e50913e245320, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=217348, objectId=9f0d21e348f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0d21e348f1, replyNumber=0, likeNumber=94, createdTime=2021-09-21, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0d21e348f1, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0d21e348f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372452, encodeId=cc9113e2452ff, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发, objectType=article, longId=214726, objectId=0cd1214e26c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cd1214e26c8, replyNumber=0, likeNumber=138, createdTime=2021-07-25, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cd1214e26c8, moduleTitle=Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cd1214e26c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372451, encodeId=7ccf13e2451e8, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能 , objectType=article, longId=213730, objectId=ab39213e3061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab39213e3061, replyNumber=0, likeNumber=82, createdTime=2021-07-06, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab39213e3061, moduleTitle=Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab39213e3061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372450, encodeId=1b3013e245079, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Leukemia：iFCG化疗方案治疗携带IGHV突变且无TP53突变的慢性淋巴细胞白血病, objectType=article, longId=212646, objectId=63c52126468a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63c52126468a, replyNumber=0, likeNumber=115, createdTime=2021-06-13, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63c52126468a, moduleTitle=Leukemia：iFCG化疗方案治疗携带IGHV突变且无TP53突变的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63c52126468a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372449, encodeId=195913e244967, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Br J Cancer：TP53突变增加横纹肌肉瘤和尤文肉瘤的放疗抗性, objectType=article, longId=212076, objectId=595a2120e61c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=595a2120e61c, replyNumber=0, likeNumber=120, createdTime=2021-06-01, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=595a2120e61c, moduleTitle=Br J Cancer：TP53突变增加横纹肌肉瘤和尤文肉瘤的放疗抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=595a2120e61c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372448, encodeId=5aff13e24484d, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Nature Immunology：美国密西根大学邹伟平团队揭示MDM2-p53抑制剂肿瘤免疫学新机制, objectType=article, longId=209096, objectId=ca1f2090962d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca1f2090962d, replyNumber=0, likeNumber=89, createdTime=2021-03-29, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca1f2090962d, moduleTitle=Nature Immunology：美国密西根大学邹伟平团队揭示MDM2-p53抑制剂肿瘤免疫学新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca1f2090962d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372447, encodeId=05e413e244797, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Science：可靶向RAS与p53蛋白受体，双特异性抗体研究再获突破！, objectType=article, longId=207870, objectId=526820e870f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=526820e870f8, replyNumber=0, likeNumber=87, createdTime=2021-03-05, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=526820e870f8, moduleTitle=Science：可靶向RAS与p53蛋白受体，双特异性抗体研究再获突破！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=526820e870f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372446, encodeId=ad9913e2446ba, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML, objectType=article, longId=207335, objectId=402b20e335fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402b20e335fd, replyNumber=0, likeNumber=96, createdTime=2021-02-21, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402b20e335fd, moduleTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=402b20e335fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372445, encodeId=b38c13e244518, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Nat Commun：绿茶竟可增强p53的抗癌活性？, objectType=article, longId=207084, objectId=876820e084a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876820e084a7, replyNumber=0, likeNumber=71, createdTime=2021-02-14, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876820e084a7, moduleTitle=Nat Commun：绿茶竟可增强p53的抗癌活性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=876820e084a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372444, encodeId=379f13e2444da, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Blood：核糖体合成检查点激活障碍可诱导p53依赖性MCL-1降解和MYC驱动型淋巴瘤死亡, objectType=article, longId=206234, objectId=fb9020623404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb9020623404, replyNumber=0, likeNumber=137, createdTime=2021-01-27, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb9020623404, moduleTitle=Blood：核糖体合成检查点激活障碍可诱导p53依赖性MCL-1降解和MYC驱动型淋巴瘤死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb9020623404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372443, encodeId=37b113e244396, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS, objectType=article, longId=206018, objectId=3311206018ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3311206018ec, replyNumber=0, likeNumber=115, createdTime=2021-01-23, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3311206018ec, moduleTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3311206018ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372442, encodeId=f8ae13e2442a5, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标, objectType=article, longId=205873, objectId=3c432058e396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c432058e396, replyNumber=0, likeNumber=93, createdTime=2021-01-20, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c432058e396, moduleTitle=Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c432058e396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372441, encodeId=bdd813e244177, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=88, createdTime=2021-01-06, rootId=0, userName=zhishijing, userId=5d70341, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

p53

2020-05-29

zhishijing (审核中...)

前往app查看评论内容

#p53#

蜘蛛丝增强p53抗癌能力，有望开发出广谱mRNA癌症疫苗

2022-03-18

zhishijing (审核中...)

前往app查看评论内容

#p53#

AJH：p53 蛋白亚型的表达可预测多发性骨髓瘤患者的生存率

2022-03-06

zhishijing (审核中...)

前往app查看评论内容

#p53#

Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响

2022-02-09

zhishijing (审核中...)

前往app查看评论内容

#p53#

Cancers：新生儿筛查TP53 R337H变异检测和监测儿童肾上腺皮质肿瘤的早期诊断

2022-01-16

zhishijing (审核中...)

前往app查看评论内容

#p53#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2021-12-17

zhishijing (审核中...)

前往app查看评论内容

#p53#

HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化

2021-10-18

zhishijing (审核中...)

前往app查看评论内容

#p53#

J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值

2021-10-05

zhishijing (审核中...)

前往app查看评论内容

#p53#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2021-09-21

zhishijing (审核中...)

前往app查看评论内容

#p53#

Nat Cancer：化疗和错配修复缺陷协同促进TP53突变的发生和急性淋巴细胞白血病的复发

2021-07-25

医者仁心 (审核中...)

前往app查看评论内容

#p53#

Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能

2021-07-06

zhishijing (审核中...)

前往app查看评论内容

#p53#

Leukemia：iFCG化疗方案治疗携带IGHV突变且无TP53突变的慢性淋巴细胞白血病

2021-06-13

zhishijing (审核中...)

前往app查看评论内容

#p53#

Br J Cancer：TP53突变增加横纹肌肉瘤和尤文肉瘤的放疗抗性

2021-06-01

zhishijing (审核中...)

前往app查看评论内容

#p53#

Nature Immunology：美国密西根大学邹伟平团队揭示MDM2-p53抑制剂肿瘤免疫学新机制

2021-03-29

zhishijing (审核中...)

前往app查看评论内容

#p53#

Science：可靶向RAS与p53蛋白受体，双特异性抗体研究再获突破！

2021-03-05

zhishijing (审核中...)

前往app查看评论内容

#p53#

J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML

2021-02-21

zhishijing (审核中...)

前往app查看评论内容

#p53#

Nat Commun：绿茶竟可增强p53的抗癌活性？

2021-02-14

zhishijing (审核中...)

前往app查看评论内容

#p53#

Blood：核糖体合成检查点激活障碍可诱导p53依赖性MCL-1降解和MYC驱动型淋巴瘤死亡

2021-01-27

zhishijing (审核中...)

前往app查看评论内容

#p53#

J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS

2021-01-23

zhishijing (审核中...)

前往app查看评论内容

#p53#

Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标

2021-01-20

zhishijing (审核中...)

前往app查看评论内容

#p53#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-01-06

科室
- - 订阅+
  - 更多科室
工具
服务